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Original StudieS
Background: The impact of SARS-CoV-2 on neonates remains largely 
unknown in low- and middle-income countries (LMICs). We provide an 
epidemiologic and clinical report of SARS-CoV-2 infections in neonates 
hospitalized in Bangladesh.
Methods: Outborn neonates admitted to Dhaka Shishu Hospital, a tertiary-
care referral hospital, between 29 March and 1 July were screened for SARS-
CoV-2. We reviewed clinical data, including chest radiograph and laboratory 
reports, and conducted SARS-CoV-2 genome sequencing. Patients were 
followed-up for 27–75 days. A subset of caregivers was also tested.
Results: Of 83 neonates tested, 26 were positive (median age 8 days). Most 
neonates were admitted with diagnosis unrelated to SARS-CoV-2: 11 pre-
sented with serious non-communicable diseases, 7 with early-onset sepsis, 
5 with late-onset sepsis and 2 with pneumonia. In 3 of 5 chest radiograph, 
infiltrates and ground-glass or patchy opacities were noted. Two neonates 
developed metabolic acidosis, one developed disseminated intravascular 
coagulation. Most SARS-CoV-2 positive neonates were referred to govern-
ment-designated COVID-19 hospitals, leading to gaps in treatment. Twenty-
three neonates could be followed-up: 12 were healthy, 8 died and 3 were still 
seeking medical care. Of 9 caregivers tested, 8 were positive.
Conclusions: SARS-CoV-2 may have serious adverse effects on children 
born in LMICs. The virus likely contributed directly to two deaths, but 
the remaining 6 neonates who died had serious comorbidities. Positive 
SARS-CoV-2 test results led to gaps in immediate clinical care for other 
morbidities, which likely contributed to adverse outcomes. This case series 
emphasizes the need to understand COVID-19 in neonates in LMICs and 
its indirect impacts.
Key Words: SARS-CoV-2, COVID-19, neonates, low- and middle-income 
country, Bangladesh
(Pediatr Infect Dis J 2020;39:e398–e405)
The ongoing SARS-CoV-2 pandemic has led to over 25 mil-lion cases and caused at least 854,000 deaths worldwide as of 
August 31, 2020, 15% of which have been reported from South 
Asia.1 However, limited data are available on the epidemiology of 
the disease in this region. In addition, numerous reports describing 
COVID-19 in children are becoming available, but little is known 
about the clinical presentation and outcomes in children in South 
Asia. The evidence gap is even wider in case of neonates (<29 days 
old).
Although some studies suggest that children may be less vul-
nerable to SARS-CoV-2 infections than adults, with the exception 
of pediatric multisystem inflammatory syndrome,2 this evidence 
is equivocal and evolving as non-pharmaceutical interventions 
change (eg, school closures).3 There is a lack of evidence relating 
to neonates specifically. The first case of neonatal SARS-CoV-2 
infections was identified on February 2, 2020 in China.4 Since 
then, approximately 70 cases have been described, and symptoms 
ranged from mild to severe, and no deaths have been reported thus 
far.5–9 However, little is known about infection amongst neonates 
in South Asia, which already shares a disproportionately high bur-
den of global neonatal morbidity and mortality.10,11 By August 31, 
2020, there had been over 43 million infections and 77,000 deaths 
in South Asia, but only 2 sporadic reports on the impact of SARS-
CoV-2 on neonates in this region had been published.6,12
In this study, we report a series of 26 cases of SARS-CoV-2 
infections in neonates who presented at Dhaka Shishu Hospital 
(DSH), the largest pediatric tertiary care, referral hospital in Bang-
ladesh. We outline the hospital clinical records, chest radiograph, 
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hematologic, biochemical and molecular tests, genome sequences 
and follow-up data for these cases. Our findings highlight the direct 
and indirect impact of SARS-CoV-2 infections on neonates in South 
Asia and provide a snapshot of the presentation of these cases.
METHODS
Study Site, Design and Participants
This observational prospective study was conducted in 
DSH, which provides primary to tertiary care to children and treats 
37% of patients free of cost. This is the largest referral hospital for 
children in Bangladesh, and very sick children requiring immediate 
or intense care are referred to this hospital.
Starting in March 2020, the government of Bangladesh 
established designated COVID-19 hospitals across the country, 
but for the duration of this study, DSH was not one of them. 
However, DSH continued to admit children requiring medi-
cal attention. Children with COVID-19 symptoms were admit-
ted in an isolation ward till SARS-CoV-2 tests were conducted, 
and results were attained. In addition, children admitted at DSH, 
who required surgical procedures or ICU care, were also tested 
for SARS-CoV-2 for screening. Cases that tested positive were 
referred to a COVID-19 hospital.
This study recruited neonates (0–28 days) who presented at 
DSH between 29 March and 1 July and tested positive for SARS-
CoV-2. Between 9 June and 1 July, nasopharyngeal specimens were 
also collected from the immediate caregiver of these neonates.
Specimen Collection and Testing
Nasopharyngeal specimens were collected by trained physi-
cians or nurses using a COPAN FLOQswab (503CS01; COPAN 
Diagnostics, Brescia, Italy), which was immediately transferred 
into a 15 mL tube containing 1 mL of 1X RNA shield (D7005; 
Zymo, Irvine, CA).
All tests were performed at the Child Health Research 
Foundation that runs 4 WHO sentinel laboratories, including the 
laboratory in DSH,13 and is a government-designated testing center 
for COVID-19. RNA from all samples was extracted within 24–48 
hours of collection and tested for the presence of SARS-CoV-2 
using the TaqPath COVID-19 RT-PCR Kit (A7817; Thermo Fisher 
Scientific, Waltham, MA).
Genome Sequencing
Viral RNA was extracted from nasopharyngeal specimens 
using the Quick-RNA/DNA Microprep Extraction Kit (D7005; 
Zymo), and was converted to cDNA using ProtoScript II (E6560; 
New England Biolabs, Ipswich, MA). Libraries prepared follow-
ing the ARTIC pipeline,14 were sequenced on an Illumina iSeq100 
sequencer using 150-nucleotide paired-end sequencing. SARS-
CoV-2 reads were recovered by mapping the raw reads against the 
reference sequence (GenBank accession no. MN908947.3, https://
github.com/czbiohub/sc2-msspe-bioinfo).15,16 Consensus sequences 
of the 9 SARS-CoV-2 genomes were uploaded on GISAID17 and 
subsequently analyzed using NextStrain (https://nextstrain.org/).18
Clinical Data Collection and Analysis
Demographic and clinical data were prospectively collected 
with a standardized form for 25 of 26 cases. The hospital file of 
the first identified SARS-CoV-2 neonatal case was misplaced, 
and therefore only partial data could be retrieved retrospectively 
through telephone interviews. Laboratory data for all cases were 
collected from the COVID-19 database of the laboratory. Outcomes 
of the positive cases were followed-up over telephone through July 
28, 2020, upon consent, using structured questionnaires.
Ethical Considerations
All protocols were approved by the National Research Eth-
ics Committee, Bangladesh Medical Research Council, and the 
ethical review board of the Bangladesh Institute of Child Health. 
Samples from suspected COVID-19 patients were collected for 
clinical care and diagnostic testing at the discretion of the attending 
healthcare providers.
RESULTS
Between March 29, 2020 and July 01, 2020, nasopharyngeal 
swab specimens were tested for SARS-CoV-2 from 83 neonates 
with various medical presentations. Twenty-six neonates (31%) 
tested positive and 16 of 26 (62%) were boys. The median age of 
the positive cases was 8 days and 14 babies (53%) were in their 
first 5 days of life (Figure 1). No other etiologies were identified 
in these 26 cases. All babies were born at term, and mean weight 
at admission was 2.9 kg. Cases were followed-up through July 28, 
2020. Four babies died at the hospital, 18 were referred to hospitals 
designated to treat COVID-19 by the Government of Bangladesh. 
Of the 22 children who left DSH alive, 19 were followed-up; 12 
were healthy, 3 were still seeking medical care and 4 had died.
The main clinical and biologic characteristics, treatments and 
outcomes of the 26 patients at hospital admission are summarized in 
Table 1. Key events are illustrated in Figure 2. Detailed history of 
each case is provided in the Supplemental Digital Content 1, http://
links.lww.com/INF/E137. Of the 25 cases for which detailed hospital 
data were available, 7 cases presented with symptoms of early-onset 
neonatal sepsis (EONS), 5 with late-onset neonatal sepsis (LONS), 
2 with pneumonia and 11 with serious non-communicable diseases.
Neonates Presenting With Early Onset Neonatal 
Sepsis
Seven babies, Ne07, Ne08, Ne09, Ne11, Ne12, Ne13 and 
Ne14, presented at the hospital with clinical signs of EONS. Of spe-
cific note is patient Ne09, who also showed signs of pneumonia, and 
his chest radiograph showed bilateral ground-glass opacity indicative 
of SARS-CoV-2. The baby required supplemental oxygen, developed 
severe metabolic acidosis (see Table, Supplemental Digital Content 
2, http://links.lww.com/INF/E138) and died at the age of 6 days. 
Similarly, patient Ne08 had respiratory distress, required supplemen-
tal oxygen and showed signs of disseminated intravascular coagula-
tion and eventually died on the sixth day of hospitalization, at the age 
of 8 days. Patients Ne12 and N14, who were admitted with neonatal 
jaundice, and Ne11 were referred to COVID-19 hospitals. Ne12 was 
lost to follow-up and Ne14 and Ne11 were doing well during fol-
low-up. Ne07 and Ne13 were admitted with perinatal asphyxia and 
hypoxic-ischemic encephalopathy (HIE) stage 2 along with EONS. 
Chest radiograph of Ne07 showed patchy opacities in the right lower 
lobe suggesting pneumonia (Fig. 3A) and chest radio graph of Ne13 
showed patchy opacities in the right lower perihilar region indicating 
nonspecific inflammatory lesion (Fig. 3D). Ne07 was still seeking 
medical attention during follow-up, and Ne13 was lost to follow-up.
Neonates Presenting With Late-onset Neonatal 
Sepsis
Five children were admitted with signs of LONS: Ne16, 
Ne19, Ne20, Ne24 and Ne25. Among them, 3 patients, Ne16, 
Ne19 and Ne20 presented with fever; in addition, Ne19 had res-
piratory distress and Ne20 had convulsions. Ne16 and Ne19 were 
referred to a COVID-19 hospital after 2 and 3 days, respectively, 
and Ne20 was discharged after 8 days. All 3 patients were doing 
well during follow-up. Patients Ne24 and Ne25 showed signs of 
pneumonia with bilateral crepitations during admission. Ne24 
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was referred to a COVID-19 hospital after 2 days, and family of 
Ne25 left after 4 days. During follow-up, both these children were 
also doing well.
Neonates Presenting With Pneumonia
Patient Ne02 and Ne23 presented with signs of pneumonia. 
Ne02 was admitted with perinatal asphyxia and HIE stage 2, and 
congenital pneumonia with bilateral crepitations. The child died 
after 2 days, at the age of 3 days. Patient Ne23 presented with fever, 
respiratory distress and bilateral crepitations and also required sup-
plemental oxygen. After 4 days at DSH, the baby was referred to a 
COVID-19 hospital and was lost to follow-up.
Neonates Presenting With Non-communicable 
Diseases
Eleven cases presented with serious non-communicable dis-
eases at admission. These cases were screened for SARS-CoV-2 
before surgery, before admission into the critical-care unit or due to 
contact history. Ne01, Ne03 and Ne10 were admitted with ruptured 
myelomeningocele, Ne04 had anocutaneous fistula, Ne05 with rup-
tured occipital encephalocele, Ne06 with anorectal malformation, 
Ne15 and Ne17 with obstructive uropathy, Ne18 and Ne21 with con-
genital heart disease, and Ne22 with epistaxis due to fall from height.
For 3 cases (Ne03, Ne04, Ne05) emergency surgeries 
were performed soon after hospital admission before the SARS-
CoV-2 test results were obtained. For postoperative care, they were 
referred to COVID-19 hospitals. All 3 children were reported to be 
doing well during follow-up. Three other cases that also required 
surgeries (Ne01, Ne10, Ne15) were referred to COVID-19 hos-
pitals immediately after SARS-CoV-2 test results were obtained. 
Ne01 died at another hospital at the age of 38 days; Ne10 had 1 
surgery and was reported to be waiting for a second surgery during 
a telephone follow-up 40 days of testing positive; Ne15 was also 
still sick and seeking medical care.
FIGURE 1. Age distribution 
and outcome of neonatal cases 
of SARS-CoV-2.
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Ne06, admitted with anorectal malformation, died the day 
after admission due to sepsis. Ne18 and Ne21, both of whom were 
admitted due to congenital heart disease, developed signs of respir-
atory distress. Ne18 also developed LONS and metabolic acidosis 
(arterial blood gas results are shown on Table, Supplemental Digital 
Content 2, http://links.lww.com/INF/E138) and was referred to a 
COVID-19 designated hospital; however, the family did not seek 
care at any other hospital and the child died at home at the age of 25 
days. Ne21 was also referred to a COVID-19 hospital after 4 days, 
and died at the age of 30 days.
Ne17 was admitted with posterior urethral valve with bilat-
eral hydroureteronephrosis, with bilateral talipes equinovarus. 
After 8 days, the patient was referred to a COVID-19 hospital, 
where he died at the age of 28 days. Ne22 was admitted with 
epistaxis due to fall, discharged after 4 days, and was doing well 
during follow-up. Overall, cases referred to designated COVID-
19 hospitals due to a SARS-CoV-2 positive result, despite other 
serious morbidities that required immediate and constant care, 
suffered from delays and gaps in treatment. Some families went 
home instead of seeking care at another hospital that also led to 
adverse outcomes.
Maternal SARS-CoV-2 Infection
Twenty of the 26 families could be interviewed to deter-
mine potential exposure to SARS-CoV-2, and in total, 6 moth-
ers reported experiencing COVID-19 related symptoms in the 
days before delivery. Immediate caregivers from 9 neonates (8 
mothers and 1 grandmother) provided nasopharyngeal swab 
specimens during the time of specimen collection from the 
neonates; 8 of them tested positive for SARS-CoV-2 (see Table, 
Supplemental Digital Content 2, http://links.lww.com/INF/
E138), and 4 of them exhibited COVID-19 symptoms. Amongst 
the mothers who were not tested, 2 reported symptoms related 
to COVID-19.













Outcome (Age at 
Follow-up/Death)
Ne01 0/f Ruptured myelomeningocele Ceftriaxone 3 Referred Died (38)
Ne02 1/f PNA with HIE stage 2 and congenital 
pneumonia
Ceftazidime, amikacin, phenobarbitone, 
Sup 02
2 Died (3) —
Ne03 1/f Ruptured myelomeningocele Surgical repair, ceftazidime, gentamycin, 
paracetamol
3 Referred Healthy (59)
Ne04 1/m Anocutaneous fistula Anoplasty, ceftazidime, metronidazole 3 Referred Healthy (61)
Ne05 1/f Ruptured occipital encephalocele Excision and repair of occipital region, 
ceftriaxone, flucloxacillin, gentamicin, 
phenobarbitone
12 Referred Healthy (74)
Ne06 2/m EONS with anorectal malformation Nasogastric suction, ceftazidime, amika-
cin, metronidazol
1 Died (4) —
Ne07 2/m PNA with HIE stage 2, pneumonia and 
EONS
Ceftazidime, amikacin, meropenem, 
netilmicin, phenobarbitone, Sup 02
10 LAMA Sick (36)
Ne08 3/f EONS with disseminated intravascular 
coagulation
Ceftazidime, amikacin, meropenem, vanco-
mycin, dopamine, dobutamine, Sup 02
5 Died (8) —
Ne09 4/m EONS, pneumonia, and severe meta-
bolic acidosis
Ceftazidime, amikacin, dopamine, sodium 
bicarbonate, Sup 02
2 Died (6) —
Ne10 4/f Ruptured myelomeningocele Ceftriaxone, gentamycin 4 Referred Sick (40)
Ne11 4/f EONS Ceftazidime, amikacin, Sup 02 3 Referred Healthy (63)
Ne12 4/m EONS and neonatal jaundice Ceftazidime, phototherapy 3 Referred LTFU
Ne13 4/m PNA with HIE stage 2, EONS and 
pneumonia
Ceftazidime, amikacin, meropenem, 




Ne14 5/f EONS and neonatal jaundice Ceftazidime, amikacin, phenobarbitone, 
Sup 02
5 Referred Healthy (49)
Ne15 8/m Acute kidney injury due to obstructive 
uropathy
 Ceftazidime, meropenem, sodium bicarbo-
nate, calcium gluconate
4 Referred Sick (63)
Ne16 8/m LONS Ceftazidime, amikacin 2 Referred Healthy (70)
Ne17 14/m Posterior urethral valve with bilateral 
hydroureteronephrosis (grade-3) with 
bilateral TEV
Ceftazidime, amikacin, meropenem, metro-
nidazole, frusemide, calcium gluconate, 
sodium bicarbonate
7 Referred Died (28)
Ne18 19/m Congenital heart disease, LONS and 
metabolic acidosis
Meropenem, amikacin, aminophylline, 
phenobarbitone, Sup 02
5 Referred Died (25)
Ne19 22/m LONS Ceftazidime, amikacin, Sup 02 3 Referred Healthy (49)
Ne20 22/m LONS Ceftriaxone, amikacin, phenobarbitone 8 Discharged Healthy (81)
Ne21 23/m Congenital heart disease and LONS Ceftazidime, meropenem, dobutamine, 
furosemide, calcium gluconate, Sup 02
4 Referred Died (30)
Ne22 23/m Epistaxis due to local trauma Mupirocin 2% topical ointment 4 Referred Healthy (57)
Ne23 23/m Pneumonia Ceftazidime, amikacin, Sup 02 4 Referred LTFU
Ne24 25/f LONS and pneumonia  Ceftriaxone, amikacin, Sup 02 2 Referred Healthy (82)
Ne25 28/f LONS and pneumonia Meropenem, amikacin 4 LAMA Healthy (77)
Ne26 28/m NA NA 6 Discharged Healthy (102)
All ages are in days.
TEV indicates talipes equinovarus; PNA, perinatal asphyxia; AGA, appropriate gastrointestinal age; RDS, respiratory distress syndrome; LTFU, lost to follow-up; LAMA, left 
against medical advice; NA, not available.
Saha et al The Pediatric Infectious Disease Journal • Volume 39, Number 12, December 2020
e402 | www.pidj.com © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.
Genome Sequencing and Geographic Distribution
Genome sequences were obtained from 9 neonatal cases that 
had cycle threshold value of less than 25 for nucleoprotein gene 
(specimens with high viral RNA concentration). These clustered 
with other Bangladeshi isolates in clades 20A, 20B and 20C (see 
Figure, Supplemental Digital Content 3, http://links.lww.com/INF/
E139), and no specific distinct cluster was seen for these cases. 
The residential locations of the cases were distributed across the 
country (see Figure, Supplemental Digital Content 4, http://links.
lww.com/INF/E140).
DISCUSSION
There are emerging reports of SARS-CoV-2 infection in 
children and some studies have also indicated that COVID-19 in 
children may present with atypical symptoms.2,19,20 This is of spe-
cific concern to low- and middle-income countries (LMICs), where 
newborns are already the most vulnerable population, and several 
reports indicate the decline in essential care due to the pandemic.21
This study, to our knowledge, presents the largest case series 
of SARS-CoV-2 infections in neonates to date. We screened 83 
babies admitted at a tertiary care pediatric hospital, and 26 (31%) 
tested positive for SARS-CoV-2 by RT-qPCR. We recorded a wide 
spectrum of presenting signs and symptoms. These included fever, 
respiratory distress, gastrointestinal symptoms and a range of non-
communicable morbidities like perinatal asphyxia and HIE that 
are commonly reported as neonatal causes of hospitalization and 
deaths in this region. Three of the 5 chest radiographs available 
showed changes consistent with pneumonia. Previous publications 
on neonatal COVID-19 cases have identified fever, respiratory dis-
tress and ground-glass opacity in chest radiographs as the most 
common symptoms in neonates;7,22 presentation of gastrointestinal 
symptoms have also been noted.5
Of the 8 babies who died, 6 had serious co-morbidities—
ruptured myelomeningocele, perinatal asphyxia and HIE stage 2 
and congenital pneumonia, anorectal malformation, posterior ure-
thral valve with bilateral hydroureteronephrosis, and congenital 
heart disease. These morbidities have been associated with high 
mortality in LMICs,11 and therefore it is difficult to determine the 
role of SARS-CoV-2 in death. However, it is clear that in both chil-
dren and adults, severity of and mortality due to COVID-19 are 
amplified in patients with specific preexisting morbidities.23,24 This 
might also be the case in neonates, where SARS-CoV-2 infection 
might aggravate the health of already vulnerable children.
In 2 patients who died, Ne08 and Ne09, SARS-CoV-2 infec-
tion was likely the key contributor. Ne09 was admitted with EONS 
and developed severe metabolic acidosis; chest radiograph showed 
bilateral ground-glass opacity. Both the bilateral ground-glass opac-
ity and metabolic acidosis have been reported in severe COVID-
19 patients.25–27 Ne08 presented with respiratory distress and was 
diagnosed with EONS with disseminated intravascular coagulation, 
which has been reported in severe COVID-19 patients.28 Both the 
babies died before they reached the ninth day of life. These 2 cases 
provide evidence that SARS-CoV-2 infections may lead to systemic 
disease with adverse outcomes in neonates.
In addition to the direct impact of SARS-CoV-2 on neo-
nates, this snapshot of vulnerable neonates born in LMICs in the 
midst of the COVID-19 pandemic and the loss of care or atten-
tion, depict the indirect impacts this virus can have on neonatal 
health. For example, the family of baby Ne10 is still waiting for a 
surgery, and baby Ne01 died at the age of only 38 days when the 
family was still waiting for a surgery. Such surgeries are routinely 
performed at DSH but due to the pandemic (and sometimes due 
FIGURE 2. Overview of the key events of the 26 SARS-CoV-2 neonatal infections. This includes dates of hospital admission 
and other key events for each case during the course of this surveillance study.
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to infections of health care providers themselves), cases had to be 
referred to general COVID-19 designated hospitals. Such delays 
in medical treatment are likely to have serious outcomes in the 
near future.
To confirm the positive results seen in the RT-qPCR assays, 
SARS-CoV-2 genome sequences were obtained from 9 cases with 
high viral loads. Considering that the SARS-CoV-2 genomes 
belonged to different clades, and tests were conducted within 72 
FIGURE 3. Chest radiograph 
images of 5 neonates with 
SARS-CoV-2 infections. A: Chest 
radiograph of Ne07 showed 
patchy opacities in right lower 
lobe suggesting pneumonia. 
B: Chest radiograph of Ne08 
looked normal. C: Chest 
radiograph of Ne09 showed 
bilateral ground-glass opacity 
indicative of SARS-CoV-2. D: 
Chest radiograph of Ne13 
showed few patchy opacities 
in the right lower perihilar 
region indicating nonspecific 
inflammatory lesion in 
right lower zone. E: Chest 
radiograph of Ne23 looked 
normal.
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hours of admission in 19 (73%) cases, the virus was likely acquired 
before presentation at DSH, either in the household or at the hos-
pital of birth. To further investigate potential sources of infections, 
we tested samples from 9 caregivers, 8 of whom tested positive. 
Of all 20 families interviewed, 6 mothers reported experiencing 
symptoms related to COVID-19 in the days before child deliv-
ery. While it was out of the scope of this study to further examine 
vertical or horizontal transmission from mother, this does suggest 
that neonatal infections are likely to increase if SARS-CoV-2 con-
tinues to spread in the population, and preventative policies need 
to be designed and instituted immediately to protect children from 
acquiring the infection in this critical period of their development.
The findings of this study should be considered within the 
context of several limitations. First, DSH does not have a mater-
nity facility and hence neonates were only admitted here if they had 
serious conditions, biasing our findings towards the most severe 
outcomes. Our surveillance did not include asymptomatic SARS-
CoV-2 positive neonates and their outcomes. Second, as also alluded 
to above, most of the babies that tested positive were referred to 
government-designated COVID-19 hospitals and this transfer led to 
a gap in their treatment that could have negatively impacted their 
outcome (4 babies died after leaving DSH). Third, due to reduced 
hospital capacity because of COVID-19, chest radiographs were 
only performed on 5 cases, and limited laboratory tests were con-
ducted, inhibiting more nuanced understanding of the inflammatory 
state of the neonates. Finally, the study only followed up patients for 
27–75 days after testing positive. It has been reported that children 
with exposure to SARS-CoV-2 can have serious long-term effects 
like multisystem inflammatory response months after the infection.2
Despite these limitations, this study has important lessons 
for the design of future studies looking at SARS-CoV-2 infections 
in children, specifically neonates. First, except for 2 cases that had 
typical COVID-19 symptoms, neonates presented with one or more 
comorbidities often seen in South Asia and other LMICs. Future 
studies should take this into consideration when designing their 
inclusion criteria to capture SARS-CoV-2 infections in this age 
group. The effects of COVID-19 may manifest or become apparent 
after other presenting comorbidities have been addressed. Second, 
half of SARS-CoV-2 infections were identified within the first 5 days 
of life indicating that patients should be screened very early to cap-
ture SARS-CoV-2 infections. Finally, while it is difficult to assign 
SARS-CoV-2 as the cause of death due to multiple comorbidities 
present in these cases, including several serious noninfectious clini-
cal features, our study provides evidence that neonates with SARS-
CoV-2 infections can be adversely affected, whether directly by the 
virus, or indirectly due to lack of optimal care as a result of a posi-
tive test. We recommend that policymakers take this into account and 
provide specific attention to neonates with SARS-CoV-2 infections 
when designing treatment policies for COVID-19 treatment.
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